Evidence map›Paper›PMID 26966403›Full record

ReviewCurrent oncology (Toronto, Ont.)2016

A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

S Lachance, A L Christofides, J K Lee, L H Sehn, B C Ritchie, C Shustik, D A Stewart, C L Toze, E Haddad, D C Vinh

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03730129 (A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03730129 phase2 / phase3completednot on this mapstarted 2018, after this paper: background citation

A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity

TypeinterventionalSponsorRochester General HospitalRan2018 to 2020Enrolled20ConditionsSecondary Immune Deficiency DisorderArmsHizentra
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022
    Article
  7. Review
  8. Article
  9. Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?Hematology/oncology clinics of North America · 2021
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

S LachanceUniversité de Montréal, Montreal, QC;
A L ChristofidesNew Evidence, Toronto, ON;
J K LeeCanadian Society of Allergy and Clinical Immunology, Toronto, ON;
L H SehnBC Cancer Agency, Vancouver, BC;
B C RitchieUniversity of Alberta, Edmonton, AB;
C ShustikMcGill University Health Centre, Montreal, QC;
D A StewartTom Baker Cancer Centre, Calgary, AB;
C L TozeLeukemia/Bone Marrow Transplant Program of BC, Vancouver General Hospital, BC Cancer Agency, and University of British Columbia, Vancouver, BC;
E Haddadchu Sainte-Justine, Departments of Pediatrics and of Microbiology, Immunology, and Infectiology, Université de Montréal, Montreal, QC.
D C VinhMcGill University Health Centre, Montreal, QC;
McGill University Health Centre · CABC Cancer Agency · CACanadian Nutrition Society · CACentre Hospitalier Universitaire Sainte-Justine · CAEvidence (Italy) · ITUniversité de Montréal · CAUniversity of Alberta · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (cll), who typically have increased susceptibility because of hypogammaglobulinemia (hgg) related to their disease and its treatment. Immunoglobulin replacement therapy (igrt) has been shown to reduce the frequency of bacterial infections and associated hospitalizations in patients with hgg or a history of infection, or both. However, use of igrt in cll is contentious. Studies examining such treatment were conducted largely before the use of newer chemoimmunotherapies, which can extend lifespan, but do not correct the hgg inherent to the disease. Thus, the utility of igrt has to be re-evaluated in the current setting. Here, we discuss the evidence for the use of igrt in cll and provide a practical approach to its use in the prevention and management of infections.

Indexed as

Chronic lymphocytic leukemiahypogammaglobulinemiaimmunodeficiencyimmunoglobulin replacement therapyimmunoglobulinsinfectionivigscig

Identifiers

PMID26966403
PMCPMC4754059
OpenAlexW2286356945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.